Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1

• Published in: Frontiers in cardiovascular medicine 2023-06, Vol.10, p.1060030-1060030
• Main Authors: Trohman, Richard G, Huang, Henry D, Sharma, Parikshit S
• Format: Article
• Language: English
• Subjects: Cardiovascular Medicine; catheter ablation—atrial fibrillation; epidemiology; lifestyle modification; pathophysiology; pharmacological interventions
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2023.1060030

Atrial fibrillation (AF), is the most common sustained cardiac arrhythmia. It was once thought to be benign as long as the ventricular rate was controlled, however, AF is associated with significant cardiac morbidity and mortality. Increasing life expectancy driven by improved health care and decreased fertility rates has, in most of the world, resulted in the population aged ≥65 years growing more rapidly than the overall population. As the population ages, projections suggest that the burden of AF may increase more than 60% by 2050. Although considerable progress has been made in the treatment and management of AF, primary prevention, secondary prevention, and prevention of thromboembolic complications remain a work in progress. This narrative review was facilitated by a MEDLINE search to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, and other clinically relevant studies. The search was limited to English-language reports published between 1950 and 2021. Google and Google scholar as well as bibliographies of identified articles were reviewed for additional references. In these two manuscripts, we discuss the current strategies available to prevent AF, then compare noninvasive and invasive treatment strategies to diminish AF recurrence. In addition, we examine the pharmacological, percutaneous device and surgical approaches to prevent stroke as well as other types of thromboembolic events.